Cara Therapeutics to Present at the BofA Securities 2021 Virtual Health Care Conference

Rhea-AI Summary

Cara Therapeutics, Inc. (Nasdaq: CARA) will have its President and CEO, Derek Chalmers, participate in a fireside chat at the BofA Securities 2021 Virtual Health Care Conference on May 13, 2021, at 11:00 a.m. ET. Investors can access a live webcast on the company's website, with an archived version available for 30 days post-event. Cara focuses on developing treatments for pruritus, with its lead candidate, KORSUVA™ (difelikefalin), showing significant results in Phase 3 trials. The FDA has set a target action date of August 23, 2021, for KORSUVA's NDA.

STAMFORD, Conn., May 06, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer, will participate in a fireside chat at the BofA Securities 2021 Virtual Health Care Conference on Thursday, May 13, 2021 at 11:00 a.m. ET.

A live webcast of the presentation can be accessed under "Events & Presentations" in the News & Investors section of the Company's website at www.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website for approximately 30 days.

About Cara Therapeutics

Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs. Cara is developing a novel and proprietary class of product candidates, led by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. In two Phase 3 trials, KORSUVA Injection has demonstrated statistically significant reductions in itch intensity and concomitant improvement in quality of life measures in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP). The U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the New Drug Application (NDA) for KORSUVA™ (difelikefalin) solution for injection for the treatment of moderate-to-severe pruritus in hemodialysis patients. The PDUFA target action date for KORSUVA is August 23, 2021. Oral KORSUVA™ has completed Phase 2 trials for the treatment of pruritus in patients with CKD and AD and is currently in Phase 2 trials in primary biliary cholangitis and notalgia paresthetica patients with moderate-to-severe pruritus.

The FDA has conditionally accepted KORSUVA™ as the trade name for difelikefalin injection. CR845/difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.

MEDIA CONTACT:
Claire LaCagnina
6 Degrees
315-765-1462
clacagnina@6degreespr.com 

INVESTOR CONTACT:
Janhavi Mohite
Stern Investor Relations, Inc.
212-362-1200
janhavi.mohite@SternIR.com 

FAQ

What is the date and time for the CARA fireside chat at the BofA Securities Conference?

The fireside chat featuring Cara Therapeutics' CEO will occur on May 13, 2021, at 11:00 a.m. ET.

How can investors access the webcast for the CARA fireside chat?

Investors can access the live webcast under the 'Events & Presentations' section on Cara Therapeutics' website.

What is KORSUVA and what are its market prospects?

KORSUVA is Cara Therapeutics' lead candidate for treating pruritus, with significant trial results and an NDA under Priority Review by the FDA.

What is the PDUFA date for CARA's KORSUVA drug application?

The PDUFA target action date for KORSUVA's New Drug Application is August 23, 2021.

What conditions is KORSUVA being developed to treat?

KORSUVA is being developed to treat moderate-to-severe pruritus in hemodialysis patients and has completed trials for other conditions.